{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:20:43Z","timestamp":1793996443261,"version":"4.8.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dyslipidemia may be an important modifiable risk factor contributing to the increased cardiovascular risk in inflammatory bowel disease (IBD). The lipid metabolism is subject to both systemic inflammation and drug therapy; however, it is unclear if this effect is drug-class dependent. Our aim was to assess lipid changes after IBD induction therapy and evaluate associated factors with a particular focus on drug class and disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective study, consecutive IBD patients starting systemic therapy (eg, corticosteroids, thiopurines, methotrexate, anti-TNF-\u03b1 agents, vedolizumab, ustekinumab, and tofacitinib) were included. Primary outcomes were changes in total cholesterol, high density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides at week 10.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred ninety-eight IBD patients (107 women [54%], median age 36 years; interquartile range [IQR], 27-47) were included: 137 Crohn\u2019s disease (67%), 61 ulcerative colitis (29%), and 8 IBD-unclassified (4%). Median C-reactive protein and fecal calprotectin at baseline were 5.1 mg\/L (IQR, 1.6-12.0) and 1040 ug\/g (IQR, 383-1800), respectively. Relative increases in total cholesterol, HDL-c, and LDL-c were significant after prednisone (+26%, +31%, +12%) and tofacitinib therapy (+20%, +25%, +26%), respectively. Results remained after adjusting for concomitant corticosteroids, cholestyramine, and PSC diagnosis. Changes in clinical scores were inversely correlated with total cholesterol changes (R \u2212186, P = .014), as was CRP with total cholesterol and LDL-c (R \u22120.292 and R \u22120.259, P &amp;lt; .001). No correlation was found with FCP. Lipid changes remained after adjusting for age and CRP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Prednisone and tofacitinib induction therapy significantly increase serum lipid levels, whereas no changes were observed in other drug classes. The observations seem drug-specific inasmuch as adjustment for systemic inflammation did not alter the results.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ibd\/izac100","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T04:12:01Z","timestamp":1653019921000},"page":"531-538","source":"Crossref","is-referenced-by-count":24,"title":["Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-8766","authenticated-orcid":false,"given":"Jasmijn A M","family":"Sleutjes","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-9962","authenticated-orcid":false,"given":"Jeanine E","family":"Roeters van Lennep","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Janneke","family":"van der Woude","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie C","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Erasmus Medical Center , Rotterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"15","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1177\/2047487318792952","article-title":"Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis.","volume":"25","author":"Sun","year":"2018","journal-title":"Eur J Prev Cardiol."},{"issue":"6","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"e02159","DOI":"10.1002\/brb3.2159","article-title":"Increased risk of stroke among patients with inflammatory bowel disease: a PRISMA-compliant meta-analysis.","volume":"11","author":"Chen","year":"2021","journal-title":"Brain Behav."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ecco-jcc\/jjy164","article-title":"Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals.","volume":"13","author":"Aarestrup","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/CEG.S243478","article-title":"Cardiovascular risk in individuals with inflammatory bowel disease.","volume":"13","author":"Biondi","year":"2020","journal-title":"Clin Exp Gastroenterol."},{"issue":"20","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA."},{"issue":"21","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease.","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation."},{"issue":"3","key":"2023040316444360600_","first-page":"181","article-title":"An overview of lipid abnormalities in patients with inflammatory bowel disease.","volume":"24","author":"Agouridis","year":"2011","journal-title":"Ann Gastroenterol."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10620-015-3932-1","article-title":"Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease.","volume":"61","author":"Koutroumpakis","year":"2016","journal-title":"Dig Dis Sci."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2036.2008.03886.x","article-title":"Plasma lipids and inflammation in active inflammatory bowel diseases.","volume":"29","author":"Romanato","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/apt.16580","article-title":"Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.","volume":"54","author":"Sleutjes","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MEG.0b013e328325d42b","article-title":"Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.","volume":"21","author":"Koutroubakis","year":"2009","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"4","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.clinre.2015.12.009","article-title":"Anti-TNF-\u03b1 agents and serum lipids in inflammatory bowel diseases.","volume":"40","author":"Kalkan","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"34","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J."},{"issue":"suppl_1","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1093\/ecco-jcc\/jjx180.803","article-title":"P676 correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: data from the tofacitinib OCTAVE clinical trials.","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"10","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7196\/SAMJ.7979","article-title":"The influence of glucocorticoids on lipid and lipoprotein metabolism and atherosclerosis.","volume":"104","author":"Ross","year":"2014","journal-title":"S Afr Med J."},{"key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"7270486","DOI":"10.1155\/2018\/7270486","article-title":"Lipid and bile acid dysmetabolism in Crohn\u2019s disease.","volume":"2018","author":"Uchiyama","year":"2018","journal-title":"J Immunol Res."},{"issue":"2-3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0021-9150(87)90117-1","article-title":"Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids.","volume":"63","author":"Ettinger","year":"1987","journal-title":"Atherosclerosis."},{"issue":"4","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2040622310379293","article-title":"Therapeutic benefits of budesonide in gastroenterology.","volume":"1","author":"O\u2019Donnell","year":"2010","journal-title":"Ther Adv Chronic Dis."},{"issue":"6","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis.","volume":"29","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis.","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience.","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis vs healthy volunteers and reversal by tofacitinib.","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol."},{"issue":"10","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/ibd.20931","article-title":"Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn\u2019s disease.","volume":"15","author":"Parmentier-Decrucq","year":"2009","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","article-title":"The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.","volume":"41","author":"van Sijl","year":"2011","journal-title":"Semin Arthritis Rheum."},{"issue":"6","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ibd\/izaa227","article-title":"Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management.","volume":"27","author":"Sands","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.cgh.2018.04.031","article-title":"Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases.","volume":"16","author":"Aniwan","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut."},{"issue":"12","key":"2023040316444360600_","doi-asserted-by":"crossref","first-page":"e1003432","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study.","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"key":"2023040316444360600_","author":"FDA Drug Safety Communication","year":"2021"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac100\/43772615\/izac100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/4\/531\/49733301\/izac100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/4\/531\/49733301\/izac100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:41:52Z","timestamp":1700606512000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/4\/531\/6589576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac100","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,5,19]]}}}